2017 euroPCR

Session objectives

-How a unique DES platform translates into clinical differentiation with MiStent: from premise to proven effectiveness-

Patrick W. Serruys

Professor of Cardiology at Imperial College, London

Dr. HC in Biomedical Engineering, Melbourne

THE UNIVERSITY OF MELBOURNE

Attend this session if you want:



- To know the science behind controlled elution an crystalline sirolimus (Elazer Edelman, MD, PhD)

- To hear and discuss late-breaking trial data from DESSOLVE III (Robbert J. de Winter, Msc, MD, PhD)

- To preview the MiStent OCT substudy and discuss the daily use of MiStent (Krzysztof Milewski, MD, PhD and Gennaro Sardella, MD)

MISTENT – A DES THAT COMBINES MICROCRYSTALLINE SIROLIMUS EMBEDMENT WITH FAST BIORESORBABLE POLYMER COATING





Thin-Strut Stent

- ***Cobalt-chromium***
- ***Strut thickness 64 microns***

Early Absorbable Polymer

- ***Flows off the stent struts in 45 - 60 days***
- ***Early absorbed from tissue within 90 days***

Microcrystalline Sirolimus with vessel wall embedment



Reference: Carlyle, W., et al. J. Control Release. 2012

Late-breaking session on DISSOLVE III was this morning !



Comparison of light attenuation property of neointima (Mistent vs. Xience)



OCT Analysis at 6 months (Xience)





Comparison of light attenuation property of neointima (Mistent vs. Xience)



Comparison of light attenuation property of neointima (Mistent vs. Xience)

Mistent

Xience

DESSOLVE III OCT substudy patients

Homogeneous Neointima

Neointima heterogeneity

Homogeneous Neointima

Neointima heterogeneity

Comparison of light attenuation property of neointima (Mistent vs. Xience)





Let's have our first speaker!

Late-breaking trial MiStent/Xience on OCT, Thursday Morning 11:35-11:43 ; Room 252A



OCT Analysis at 6 months (MiStent)